CN101080225A - 包含替米沙坦及氢氯噻嗪的组合治疗 - Google Patents

包含替米沙坦及氢氯噻嗪的组合治疗 Download PDF

Info

Publication number
CN101080225A
CN101080225A CNA2005800434334A CN200580043433A CN101080225A CN 101080225 A CN101080225 A CN 101080225A CN A2005800434334 A CNA2005800434334 A CN A2005800434334A CN 200580043433 A CN200580043433 A CN 200580043433A CN 101080225 A CN101080225 A CN 101080225A
Authority
CN
China
Prior art keywords
telmisartan
compositions
hydrochlorothiazide
agent
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800434334A
Other languages
English (en)
Chinese (zh)
Inventor
赫尔穆特·E·舒马赫
彼得·博姆
阿克塞尔·里德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35589356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101080225(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN101080225A publication Critical patent/CN101080225A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
CNA2005800434334A 2004-12-17 2005-12-09 包含替米沙坦及氢氯噻嗪的组合治疗 Pending CN101080225A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63706204P 2004-12-17 2004-12-17
US60/637,062 2004-12-17

Publications (1)

Publication Number Publication Date
CN101080225A true CN101080225A (zh) 2007-11-28

Family

ID=35589356

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800434334A Pending CN101080225A (zh) 2004-12-17 2005-12-09 包含替米沙坦及氢氯噻嗪的组合治疗

Country Status (15)

Country Link
EP (1) EP1827424A1 (ja)
JP (1) JP2008524136A (ja)
KR (1) KR20070097511A (ja)
CN (1) CN101080225A (ja)
AR (1) AR052052A1 (ja)
AU (1) AU2005315855A1 (ja)
BR (1) BRPI0519656A2 (ja)
CA (1) CA2589493A1 (ja)
EA (1) EA200701159A1 (ja)
IL (1) IL183944A0 (ja)
NO (1) NO20072325L (ja)
PE (1) PE20060768A1 (ja)
TW (1) TW200637546A (ja)
UY (1) UY29274A1 (ja)
WO (1) WO2006063737A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102164918A (zh) * 2008-07-31 2011-08-24 武田药品工业株式会社 固体药物组合物
CN106562973A (zh) * 2016-11-06 2017-04-19 成都先先先生物科技有限公司 一种抗高血压药物复方制剂
CN108653227A (zh) * 2018-08-09 2018-10-16 湖北舒邦药业有限公司 一种替米沙坦氢氯噻嗪片及其制备方法
WO2019033969A1 (zh) * 2017-08-15 2019-02-21 中国科学院上海药物研究所 替米沙坦与氢氯噻嗪的共晶

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8637078B2 (en) 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
SI2180882T1 (sl) † 2007-10-19 2013-05-31 Otsuka Pharmaceutical Co., Ltd. Trdni matriksni farmacevtski pripravek
EP2203158A4 (en) 2007-10-30 2012-12-26 Reddys Lab Ltd Dr PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
CA2715350C (en) 2008-03-19 2017-02-14 Ratiopharm Gmbh Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic
GB0822170D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Telmisartan with diuretic formulations
WO2010146187A2 (en) 2009-06-19 2010-12-23 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
EP2448576A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility enhancing pharmaceutical composition
WO2011002425A2 (en) * 2009-07-02 2011-01-06 Bilgig Mahmut Pharmaceutical composition increasing solubility and stability
TR200906506A2 (tr) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Telmisartan içeren katı dozaj formları.
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
WO2014119767A1 (ja) * 2013-01-31 2014-08-07 沢井製薬株式会社 テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤
JP6422868B2 (ja) * 2013-07-23 2018-11-14 第一三共株式会社 高血圧症の予防又は治療のための医薬

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
PT1854454E (pt) * 2002-01-16 2014-01-09 Boehringer Ingelheim Pharma Método para a preparação de telmisartan amorfo

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102164918A (zh) * 2008-07-31 2011-08-24 武田药品工业株式会社 固体药物组合物
CN102164918B (zh) * 2008-07-31 2014-05-07 武田药品工业株式会社 固体药物组合物
CN106562973A (zh) * 2016-11-06 2017-04-19 成都先先先生物科技有限公司 一种抗高血压药物复方制剂
WO2019033969A1 (zh) * 2017-08-15 2019-02-21 中国科学院上海药物研究所 替米沙坦与氢氯噻嗪的共晶
CN109400535A (zh) * 2017-08-15 2019-03-01 中国科学院上海药物研究所 替米沙坦与氢氯噻嗪的共晶
CN109400535B (zh) * 2017-08-15 2022-02-08 中国科学院上海药物研究所 替米沙坦与氢氯噻嗪的共晶
CN108653227A (zh) * 2018-08-09 2018-10-16 湖北舒邦药业有限公司 一种替米沙坦氢氯噻嗪片及其制备方法

Also Published As

Publication number Publication date
TW200637546A (en) 2006-11-01
AU2005315855A1 (en) 2006-06-22
PE20060768A1 (es) 2006-09-29
WO2006063737A1 (en) 2006-06-22
EP1827424A1 (en) 2007-09-05
NO20072325L (no) 2007-07-06
IL183944A0 (en) 2007-10-31
AR052052A1 (es) 2007-02-28
EA200701159A1 (ru) 2007-12-28
KR20070097511A (ko) 2007-10-04
CA2589493A1 (en) 2006-06-22
BRPI0519656A2 (pt) 2009-03-03
UY29274A1 (es) 2006-07-31
JP2008524136A (ja) 2008-07-10

Similar Documents

Publication Publication Date Title
CN101080225A (zh) 包含替米沙坦及氢氯噻嗪的组合治疗
TWI388345B (zh) 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型
CN101052381A (zh) 包含替米沙坦和氨氯地平的双层片剂
CN1921840A (zh) 多层片剂
TWI407978B (zh) 濕粒狀藥物之製備方法
CN1615123A (zh) 含有替米沙坦和利尿剂的双层药片及其制备方法
CN101052380A (zh) 双层片剂
US20110189281A1 (en) Telmisartan and hydrochlorothiazide combination therapy
JP2012530135A (ja) ジペプチジルペプチダーゼ−４阻害剤及びピオグリタゾンの併用医薬組成物
JP2011513408A (ja) メトホルミン及びジペプチジルペプチダーゼ−ｉｖ阻害剤の併用医薬組成物
WO2007106708A2 (en) Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
JP2010508266A (ja) チアジド系化合物およびアンジオテンシン−ｉｉ−受容体遮断剤を含む放出性が制御された薬学的組成物
CN1864663A (zh) 5,7,14－三氮杂四环[10.3.1.0(2,11).0(4,9)]－十六碳－2(11)3,5,7,9－五烯的药物组合物
US20110008428A1 (en) Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic
CN103083319B (zh) 一种复方缬沙坦氨氯地平固体制剂的制备工艺
WO2011147026A2 (en) A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
RU2613900C2 (ru) Фармацевтическая композиция, содержащая фимасартан и гидрохлортиазид
JP2009513543A (ja) クロルタリドンの組み合わせ
CN1780618A (zh) 替米沙坦钠盐的药物制剂
JP2013508370A (ja) ジペプチジルペプチダーゼ−４阻害剤とピオグリタゾンとの組み合わせの医薬組成物
CN104706640B (zh) 一种含有厄贝沙坦的药用组合物及其制备工艺
TW200835526A (en) Solid dosage form
TWI488658B (zh) 溶出性之改善方法
CN1146418C (zh) 血管紧张肽转化酶抑制剂和钙通道拮抗剂的定量结合物及其制备方法和在心血管疾病的治疗中的用途
CN1286844C (zh) 含有血管紧张素ⅱ受体拮抗剂和b族维生素的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20071128